Leadership Overview
Novotech has 9 executives leading key functions including strategy, operations, finance, human resources, medical affairs, legal, and marketing.
Dedicated to advancing novel therapeutics, Novotech drives innovation by partnering with biotech companies to accelerate drug development across all phases of clinical research.
Dedicated to advancing novel therapeutics, Novotech drives innovation by partnering with biotech companies to accelerate drug development across all phases of clinical research.
Leadership Roles at Novotech
John Moller - Chief Executive Officer
John Moller, the Chief Executive Officer at Novotech, directs the company's overarching strategy and global operations. Moller's leadership focuses on fostering strategic partnerships with biotech firms, ensuring Novotech's position as a premier full-service clinical Contract Research Organization (CRO). This executive guides the expansion of services to support the development of advanced and novel therapeutics. The Chief Executive Officer's responsibilities include driving market penetration and ensuring operational excellence across all geographic regions where Novotech operates. John Moller's strategic vision is critical for navigating the complex landscape of drug development and maintaining the company's commitment to accelerating therapeutic breakthroughs. His oversight ensures alignment with corporate objectives and maximizes value for stakeholders.
Ekaterina Galperina - Chief Financial Officer
Ekaterina Galperina, the Chief Financial Officer at Novotech, manages the company's financial health and strategic fiscal planning. Galperina's responsibilities encompass financial reporting, budgeting, forecasting, and capital allocation to support Novotech's growth initiatives. This executive ensures robust financial controls and compliance with all regulatory requirements. The Chief Financial Officer plays a key part in securing funding and managing investor relations, crucial for a company focused on accelerating therapeutic development. Ekaterina Galperina's financial acumen is vital for sustaining Novotech's operations and enabling strategic investments in advanced research capabilities. Her oversight guarantees financial stability and supports the long-term vision of partnering with biotech innovators.
Hussein AlRoz - Chief Operating Officer
Hussein AlRoz, the Chief Operating Officer at Novotech, oversees the execution of the company's global operational strategies. AlRoz's focus is on optimizing clinical trial processes and ensuring seamless service delivery to biotech partners. This role involves managing the day-to-day operations, driving efficiency, and implementing best practices across all functional areas. The Chief Operating Officer ensures that Novotech's infrastructure and resources effectively support the acceleration of novel therapeutic development. Hussein AlRoz's leadership is essential for maintaining high standards of quality and compliance in clinical research. By streamlining operations, AlRoz directly contributes to Novotech's ability to manage complex projects and deliver timely results for clients worldwide.
Funsho Ojebuoboh - President & Owner
Funsho Ojebuoboh, the President & Owner at Novotech, holds ultimate responsibility for the company's strategic direction and long-term vision. Ojebuoboh's leadership guides Novotech's commitment to partnering with biotech innovators and accelerating the development of novel therapeutics. This executive ensures that the company's operational framework and service offerings remain at the forefront of the clinical research industry. The President & Owner's influence is critical in shaping Novotech's culture and market presence. Funsho Ojebuoboh's ownership stake underscores a deep commitment to the company's mission of advancing medical science and delivering exceptional value to clients worldwide.
Joseph Dumais - President
Joseph Dumais, the President at Novotech, drives key strategic initiatives and operational excellence across the organization. Dumais's leadership focuses on enhancing Novotech's capabilities as a full-service clinical Contract Research Organization (CRO), particularly in supporting biotech companies developing advanced therapeutics. This executive oversees critical business functions aimed at streamlining clinical trial execution and maximizing efficiency. The President ensures that Novotech's global operations are aligned with its mission to accelerate the development of novel treatments. Joseph Dumais's strategic oversight is vital for fostering growth and maintaining Novotech's competitive edge in the dynamic biopharmaceutical landscape.
Tim Bray - Chief Human Resources Officer
Tim Bray, the Chief Human Resources Officer at Novotech, leads the company's talent acquisition, development, and retention strategies. Bray's role is critical in building and maintaining a high-performing workforce capable of supporting complex clinical research projects. This executive oversees employee relations, compensation and benefits, and organizational development initiatives. The Chief Human Resources Officer ensures that Novotech cultivates a culture that fosters innovation and collaboration, essential for partnering with biotech companies on novel therapeutics. Tim Bray's strategic approach to human capital management is fundamental to Novotech's ability to attract and retain top scientific and operational talent globally. His leadership ensures the organization is well-equipped to meet the demands of accelerating drug development.
Melinda Borrelli - Head of Medical Office Chief & Chief Marketing Officer, Operations
Melinda Borrelli, the Head of Medical Office Chief & Chief Marketing Officer, Operations at Novotech, drives both the strategic direction of medical affairs and the company's market positioning. Borrelli's dual role ensures that Novotech's operational capabilities are effectively communicated to the biotech industry, highlighting the company's expertise in accelerating novel therapeutic development. This executive oversees the integration of medical insights into marketing strategies and operational planning. The Head of Medical Office Chief & Chief Marketing Officer, Operations is instrumental in shaping Novotech's brand identity and expanding its market reach. Melinda Borrelli's leadership ensures that Novotech remains a preferred partner for biotech companies seeking comprehensive clinical research services.
Kristin Brown - Chief Legal Officer
Kristin Brown, the Chief Legal Officer at Novotech, provides strategic legal counsel and ensures compliance across all global operations. Brown's responsibilities include managing contracts, intellectual property, regulatory affairs, and corporate governance. This executive safeguards Novotech's interests and mitigates legal risks associated with clinical research and drug development partnerships. The Chief Legal Officer plays a vital role in structuring agreements with biotech companies, ensuring clarity and adherence to international legal standards. Kristin Brown's expertise is crucial for navigating the complex legal frameworks inherent in accelerating novel therapeutics. Her leadership ensures that Novotech operates with integrity and maintains the highest ethical and legal standards.
Judith Ng-Cashin - Chief Medical Officer
Judith Ng-Cashin, the Chief Medical Officer at Novotech, leads the company's medical strategy and clinical development expertise. Ng-Cashin's role is pivotal in guiding biotech partners through the complexities of therapeutic advancement, ensuring scientific rigor and optimal patient outcomes. This executive oversees the medical monitoring of clinical trials and provides critical insights into drug efficacy and safety profiles. The Chief Medical Officer ensures that Novotech's services align with the latest medical advancements and regulatory expectations for novel therapeutics. Judith Ng-Cashin's deep clinical knowledge is essential for accelerating the development of advanced treatments and reinforcing Novotech's reputation as a leading CRO.
Explore Leadership Teams in Business Services
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham,...
Company Leadership
DT
NCI is attempting to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers.
Company Leadership SJ
BG
AL
GT
The Stowers Institute for Medical Research is dedicated to uncovering the fundamental biological processes that lead to innovative approaches for diagnosing, treating, and preventing diseases. With a focus on foundational research, the institute collaborates with experts in its Technology Centers to drive transformative scientific discoveries. It also emphasizes education and outreach, supporting motivated individuals through its accredited Graduate School and various training programs. The institute's unique funding model, established by its founders, allows scientists the freedom to explore and share their findings for the betterment of humanity.
Company Leadership
KG
SLAC National Accelerator Laboratory is dedicated to exploring the fundamental workings of the universe through cutting-edge research in areas such as particle astrophysics, energy sciences, and advanced acceleration techniques. They provide powerful tools and facilities that are utilized by scientists globally to reveal nature's fastest processes and to study the cosmos. The laboratory aims to develop new technologies and sustainable energy solutions, inviting collaborations with industry partners and offering career opportunities. SLAC is committed to innovation and education, hosting public tours, scientific seminars, and resources for students and educators.
Company Leadership JT
SS
CS
YL
Frequently Asked Questions Regarding Novotech Top Executives and Leadership Team
